Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | RXRA | P19793 | 1/20 | 0.62 |
| ▸ | RXRB | P28702 | 1/20 | 0.62 |
| ▸ | TPMT | P51580 | 1/20 | 0.58 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.58 |
| ▸ | FEN1 | P39748 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.57 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.55 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KMO | O15229 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL28107074 | 1.00 | PARP1 (0.65) | PARP1NPC1RAB9ARXRARXRB | |
| SCHEMBL16865710 | 1.00 | PARP1 (0.65) | PARP1NPC1RAB9ARXRARXRB | |
| SCHEMBL38766 | 1.00 | PARP1 (0.65) | PARP1NPC1RAB9ARXRARXRB | |
| SCHEMBL28134936 | 1.00 | PARP1 (0.65) | PARP1NPC1RAB9ARXRARXRB | |
| SCHEMBL10602066 | 0.98 | PARP1 (0.63) | PARP1NPC1RAB9ARXRARXRB | |
| SCHEMBL9194552 | 0.98 | PARP1 (0.63) | PARP1NPC1RAB9ARXRARXRB | |
| Water SCHEMBL1456948 | 0.98 | PARP1 (0.63) | PARP1NPC1RAB9ARXRARXRB | |
| Ammonia Solution, Strong SCHEMBL1812467 | 0.98 | PARP1 (0.63) | PARP1NPC1RAB9ARXRARXRB | |
| Hydrochloric Acid SCHEMBL3535766 | 0.98 | PARP1 (0.63) | PARP1NPC1RAB9ARXRARXRB | |
| SCHEMBL9317541 | 0.98 | PARP1 (0.63) | PARP1NPC1RAB9ARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230356105-A1 | TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2023-11-09 | — | — | US | claimed |
| EP-4229005-A1 | TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR | Ustav organicke chemie a biochemie AV CR, v.v.i. (CZ) | 2023-08-23 | — | — | EP | claimed |
| WO-2023149908-A1 | ORGANIC ESTERS WITH ELECTRON WITHDRAWING GROUPS FOR USE IN SUBTERRANEAN FORMATIONS | HALLIBURTON ENERGY SERVICES, INC. (US) | 2023-08-10 | — | — | WO | claimed |
| WO-2022100769-A1 | TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2022-05-19 | — | — | WO | claimed |
| CN-121628982-A | Method for preparing (S) -3-chlorobenzoyl alcohol | 弈柯莱生物科技(集团)股份有限公司 | 2026-03-10 | — | — | CN | disclosed |
| EP-4634196-A1 | PERACID PROMOTERS IN THE IRIDIUM-CATALYZED HYDROSILYLATION SYNTHESIS OF HALOALKYLORGANOSILANES | Momentive Performance Materials GmbH (DE) | 2025-10-22 | — | — | EP | disclosed |
| EP-4612134-A1 | DIARYL DIAZOLE AND DIARYL TRIAZOLE DERIVATIVES FOR USE IN TREATING A DISEASE ASSOCIATED WITH KCNK13 ACTIVITY | Cerevance, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-120082479-A | Composite bacterium for biological strengthening and sludge reduction and preparation method thereof | 无锡映川环境技术有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4551568-A1 | TRPV2 CHANNEL BLOCKERS AND USE THEREOF | Ichilov Tech Ltd. (IL) | 2025-05-14 | — | — | EP | disclosed |
| EP-4536653-A2 | SIALIC ACID DERIVATIVES AND METHODS OF USING SAME | Eisai R&D Management Co., Ltd. (JP) | 2025-04-16 | — | — | EP | disclosed |
| CN-119798282-A | Fused pyridine ring-based Myt1 inhibitors | 智擎生技制药股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| WO-2025046078-A1 | ENGINEERED BACTERIA FOR IMPROVING SOIL QUALITY | CROBIO LTD (GB) | 2025-03-06 | — | — | WO | disclosed |
| EP-4093401-A1 | SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING | The Board of Regents of the University of Texas System (US) | 2022-11-30 | — | — | EP | disclosed |
| WO-2022115742-A1 | COMPOUNDS AND METHODS FOR TREATING ALCOHOL USE DISORDER | SOPHROSYNE PHARMACEUTICALS LIMITED (KY) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111833-A1 | ELECTROLYTE REGENERATION FOR ORGANIC REDOX FLOW BATTERIES BASED ON WATER-SOLUBLE PHENAZINE-BASED COMPOUNDS | CMBLU ENERGY AG (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022100769-A1 | TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR | Ustav Organicke Chemie A Biochemie AV CR v.v.i. (CZ) | 2022-05-19 | — | — | WO | disclosed |
| EP-3983378-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2022076627-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022076626-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022017975-A1 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA CROP PROTECTION AG (CH) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230356105-A1 | TETRAAZADODECANE BASED CHELATING AGENTS FOR SEPARATION OF RARE EARTH ELEMENTS AND METHOD THEREFOR | SLC39A11, AOC1, PITHD1 | PARP1 4077/4885NPC1 3806/4885RAB9A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.